Analysis of depressive episodes, their recurrence and pharmacologic treatment in primary care patients: A retrospective descriptive study

Shysset Nuggerud-Galeas, Loreto Sáez-Benito Suescun, Nuria Berenguer Torrijó, Ana Sáez-Benito Suescun, Alejandra Aguilar-Latorre, Rosa Magallón Botaya, Bárbara Oliván Blázquez

1 Institute for Health Research Aragón, Zaragoza, Spain, 2 University San Jorge, Zaragoza, Spain, 3 Department of Medicine, Psychiatry and Dermatology, University of Zaragoza, Zaragoza, Spain, 4 Department of Psychology and Sociology, University of Zaragoza, Zaragoza, Spain

Abstract

Background
Depression is one of the most prevalent health problems, frequently being a medium- and long-term condition, with a high comorbidity rate and with frequent relapses and recurrences. Although numerous studies have compared the effectiveness of specific antidepressant therapy drugs and have assessed relapses, scientific evidence on the relationship between pharmacologic treatments and recurrence is scarce. The objective of this study is to describe depressive episodes in a primary care patient cohort, the percentage of depression recurrences and the administered pharmacologic treatment, from a naturalistic perspective.

Methods
Retrospective descriptive study. 957 subjects were included. The dependent variable was a depression diagnosis and independent variables were: gender, age at time of data collection; age of onset, first-episode treatment, number of recurrences, age at recurrences, treatment prescribed for recurrences using therapeutic groups categorization.

Results
Recurrences are frequent, affecting more than 40% of the population. In the first episode, 13.69% of the patients were not prescribed pharmacological treatment, but this percentage decreased over the following depression episodes. 80.9% of the patients who did not receive drug treatment in the first depression episode did not experience subsequent episodes. Monotherapy, and specifically, SSRIs were the most frequently prescribed treatment
Introduction

Depression is one of the most prevalent health problems in primary care, [1–3] and is one of the four medical conditions causing the largest number of disabilities [1,4,5]. Women typically have a two-fold increased risk of major depression as compared to men [6], and the peak age of risk for the first onset of a major depressive episode (including bipolar depression) is estimated to range from mid-late adolescence to the early 40s [7]. It is also the most expensive mental disorder, accounting for 1% of the Gross Domestic Product (GDP) of the European Union [8–10]. This mental health problem is often a medium- and long-term condition, having a high comorbidity rate [11,12].

Major depressive disorder (MDD) is highly recurrent [2,3,13], making the prevention of depressive relapse and recurrence depression one of the most important challenges to its management [14]. The ‘MacArthur Research Network on the Psychobiology of Depression’ proposed operational criteria for the constructs of response, remission, recovery, relapse and recurrence [3,15,16] as guidance for the field. According to these criteria, remission occurs when symptoms have largely normalized and the patient can be considered well for a given period of time (often defined as two months or longer), and precedes both recovery and recurrence. Relapse suggests the reemergence of depression symptoms (presumably part of the depressive episode) following some degree of remission but preceding recovery; and recurrence implies the onset of a new depression episode following an extended period of remission, sufficiently long so as to assume that recovery had taken place.

Recurrences occur frequently [17,18]. Individuals suffering from an initial depressive episode have a 40% to 60% chance of experiencing a subsequent episode; individuals with 2 episodes have approximately 60% to 70% possibility; and for individuals experiencing three episodes, the risk is up to 90% [3,17,19,20]. The mean time of the recurrence following the initial episode is approximately three years, and subsequent episodes usually appear after 1 or 1.5 years. Recurrence risk is higher during the initial months following recovery [19]. Subsequently, mean time of recurrence progressively decreases, and length of recovery increases; in a study [21] performed on a Dutch population, patients suffering from major depression who recovered presented a cumulative recurrence range of 13% in 5 years, 23% in 10 years and 42% in 20 years, respectively.

Previous bibliographies have highlighted certain factors involved in the recurrence of depression, such as the severity of major depression episodes (MDE) [22,23]; the number of depressive episodes experienced [22–24], early age of onset of first MDE [22], comorbidity...
with axis I and axis II psychiatric pathology [22]; change in the size of specific brain areas [25]; immunologic irregularities [26]; history of suicide attempts [22]; family history of depression [27]; concurrent physical health problems and psychosocial difficulties [28]; stressful live events [29], and female gender and older age [22].

As for drug therapy, interruption of antidepressant treatment when in remission from the depressive episode leads to a risk of recurrence in 40–50% of the patients, whereas maintaining the treatment for 6 to 12 months after remission reduces this risk to 13–20% [30–32].

Although many studies have compared the effectiveness of specific antidepressant therapy drugs and have assessed relapses, there is little scientific evidence regarding the relationship between pharmacologic treatments and recurrence. To our knowledge, no studies have analyzed the relationship between antidepressant pharmacologic strategies and depression recurrence. Only a few meta-analyses include studies of specific drugs versus placebo, obtaining inconclusive conclusions [33–35]. Therefore, there is insufficient knowledge on the association between the different classes and combinations of psychoactive drugs and the occurrence of such relapses and recurrences.

Primary health care services are the ideal setting for carrying out recurrence prevention strategies. More than 80% of all patients suffering from depression are currently managed by primary health care and drug therapy is the first-line treatment. So, antidepressant consumption has increased over recent years in Europe [36,37]. Antidepressant use has been reported to be higher in women and it tends to increase with age [38], with selective serotonin reuptake inhibitors (SSRIs) being the top choice, according to clinical practice guidelines [39].

Therefore, the aim of this study is to describe depressive episodes in a primary care patient cohort, the percentage of depression recurrences and the administered pharmacologic treatment, from a naturalistic perspective. This article provides comprehensive insights into antidepressant trends and patterns over a 16-year period, considering the recurrence of depressive episodes.

**Methods**

**Design**
Retrospective observational cohort study.

**Study population and sample size**
Data were obtained from the clinical histories of patients over the age of 18 at a primary care center in Zaragoza (Spain) between October 2017 and February 2018. This health care center attends to 18,875 patients. From this population, patients were selected based on the following inclusion criteria: 1) Aged 18 and over; 2) having been diagnosed with major depression (codified as depressive disorder according to the World Organization of Family Doctors (WONCA) ICPC-2) diagnosed by his/her primary care physician between 2001 and 2017. Exclusion criteria were: 1) Database inconsistencies; 2) having a clinical history of less than two years at the time of the study; 3) having a severe psychiatric disorder comorbidity (schizophrenia or bipolar disorder); 4) presenting dysthymia and 5) patients referred to and followed up on by the psychiatric unit.

The population cared for in this health center is aged, having an aging rate of 224.65%, an over-aging rate of 17.53%, and with 22.05% being immigrants. The percentage of males is 47.60%, having a mean age of 45 years and 10 months, whereas women account for 52.40%, with a mean age of 48 years and 10 months. The percentage of the population aged 25 and younger is 21.25% and those over the age of 60 account for 27.2% [40].
The sample size included 957 subjects meeting the selection criteria. Fig 1 shows the flow-chart of the sample size.

**Study variables and data collection**

Data were collected retrospectively from the computerized clinical histories of all primary care patients assigned to the selected health care center. The dependent variable was the depression diagnosis (The P76 International Classification of Primary Care 2° edition (ICPC-2) code of the World Organization of Family Doctors (WONCA) was used). The definition of recurrence created by Frank et al. and followed in various studies [3,14,16,17] has been used. Therefore, recurrence is considered to be a diagnosis made by the family physician, for a new depression episode (after having suffered an initial episode) in the case in which there was a previous remission of a sufficient duration so as to assume that recovery had occurred. A minimum period of 6 months following the end of treatment, according to the computer-based clinical history, was considered for the definition of a recurrence episode. Since this is a retrospective study, no validation has been conducted for the diagnosis made by the family physician.
Independent variables were gender, age at time of data collection, age of onset, first-episode treatment prescription and Anatomical Therapeutic Chemical (ATC) drug code, recurrence and number of recurrences, age at recurrences, treatment prescribed for recurrences and drug ATC code, and time to recurrences. Pharmacologic treatment has been grouped according to therapeutic group (ATC classification) [41] and is shown in Table 1. Benzodiazepines were collected, despite not being antidepressants, since they are frequently prescribed for this psychopathology. Using the patient’s clinical history, it is possible to determine if the prescription is collected from the community pharmacies, so the family physician can assess the therapeutic adherence and intervene when considered necessary. In cases in which the family physician did not prescribe any pharmacological treatment, based on his/her clinical criteria, this has also been noted.

These variables were collected retrospectively from 2018 to 2001. The cut-off point was 2001, since this was the year as of which the computer-based clinical history was available and fully established at this health center. Given the universal nature of the health system and the absence of other primary health care providers, the data obtained in the study is considered to be representative of almost 100% of the population that met the study’s inclusion criteria.

**Statistical analysis**

A descriptive analysis of the sample was conducted using means and standard deviations for continuous data and frequencies and percentages for categorical data. The following non-parametric tests (Shapiro-Wilk test p-value < 0.001) were used to analyze the relationship

**Table 1. Pharmacologic treatment according to therapeutic group (ATC classification).**

| Therapeutic group                                      | Active ingredient                                                                 |
|--------------------------------------------------------|-----------------------------------------------------------------------------------|
| Benzodiazepines                                        | Alprazolam/Trankimazin, Bentazepam, Bromazepam, Clonazepam, Clorzepate Dipotassium, Diazepam, Midazolam, Ketazolam, Lorazepam, Lormetazepam, Medazepam, Piracetam, Tepazepam, Halazepam/Flurazepam |
| Selective Serotonin Reuptake Inhibitors (SSRIs)        | Citalopram, Escitalopram, Fluoxetine, Paroxetine, Sertraline, Fluvoxamine          |
| Tricyclic Antidepressants (TCAs)                       | Clomipramine, Imipramine, Amitriptyline, Tianeptine, Doxepine, Nortriptyline     |
| Serotonin–norepinephrine reuptake inhibitors (SNRIs)    | Desvenlafaxine, Duloxetine, Venlafaxine                                           |
| Norepinephrine reuptake inhibitors (NRIs)              | Reboxetine                                                                        |
| Heterocycles                                           | Mianserin, Maprotiline                                                           |
| Norepinephrine-dopamine reuptake inhibitors (NDRIs)    | Bupropion                                                                         |
| Serotonin antagonist and reuptake inhibitors (SARI)    | Trazodone                                                                         |
| Noradrenergic and specific serotonergic antidepressants (NaSSAs) | Mirtazapine                                                                      |
| Melatonin receptor agonist (MRA)                       | Agomelatine                                                                       |
| Serotonin activity modulator (SMS)                     | Vortioxetine                                                                      |
| Hypnotics                                              | Zolpidem                                                                          |
| Antiepileptic                                          | Topiramate                                                                        |
| Typical Neuroleptics                                   | Levomepromazine, Haloperidol, Trifluoperazine                                    |
| Atypical Neuroleptics                                  | Quetiapine, Risperidone, Olanzapine                                              |
| Non-specific drugs                                     | Melitracen/flupentizol, Desanol/heptaminol, Vitamin B complex, Piridoxine/Subbutiamine, Levosulpiride/sulpiride, Gabapentin |

https://doi.org/10.1371/journal.pone.0233454.t001
between demographic variables and recurrence apparition (yes/no) and the number of recurrences: Mann–Whitney U and Kruskal Wallis for numerical variables, and Chi-square and Fisher tests for categorical ones. Pharmacologic treatments were grouped into ATC categories to provide a more robust analysis.

**Ethical considerations**

The authors declare that all procedures contributing to this work comply with the ethical standards of the Declaration of Helsinki of 1975, as revised in 2008. The study protocol was approved by the Clinical Research Ethics Committee of Aragón (Spain) (PI18/029) and by the Aragon Health Service. The database of the pharmacological treatment was facilitated anonymously by the Aragon Healthcare Department. This study forms a part of another study whose main objective is to analyze the risk factors for the recurrence of a major depression episode included in the literature and specifying the weight of each of these in a sample of subjects that have experienced a major depression episode during their life. Patients wishing to participate were requested to sign an informed consent form for data collection via questionnaire.

**Results**

A total of 957 subjects were diagnosed with major depression during the study period. Of these, 708 (73.98%) were women and 249 (26.02%) were men. Their mean age was 60.95 years (SD: 17.33). As for the number of recurrences, more than half, 59.1% (566 patients) did not have recurrence events, while 40.9% (391 patients) experienced a second depressive episode. A third depression diagnosis took place in 14.8% (142 patients) and 3.8% (36 subjects) experienced a fourth depression event. Therefore, of the patients having a second episode of depression, 36.31% experienced a third event, and of these, 25.32% had a fourth depression diagnosis. The p-value (trend) revealed an increase in age as the number of recurrences increased (p(trend) < 0.001). The mean time between the first and second episodes was 4.51 years (SD: 3.35), 3.75 years (SD: 2.23) between the second and third episodes, and 3.53 years (SD: 2.23) between the third and fourth episodes. Significant differences were found between men and women, both in number of recurrences and percentage of subjects suffering from depression recurrences. The number of recurrences and age of first episode are higher for women. All of these differences are shown in Table 2.

| Table 2. Differences between men and women in number of recurrences; mean age at diagnosis of depressive episodes and time to recurrences. |
|---------------------------------------------------------------|
| **N (men / women)**                                                                                       |
| **Number of recurrences**                                                                                   |
| 249/708                                                                                                     |
| **MEN% / Mean (SD)**                                                                                         |
| 0.48 (0.73)                                                                                                   |
| **WOMEN% / Mean (SD)**                                                                                        |
| 0.63 (0.85)                                                                                                   |
| **p-value**                                                                                                   |
| 0.022                                                                                                         |
| **1st recurrence (%)**                                                                                       |
| 88/303                                                                                                       |
| 35.34%                                                                                                       |
| 42.79%                                                                                                       |
| 0.040                                                                                                         |
| **2nd recurrence (%)**                                                                                        |
| 28/114                                                                                                       |
| 11.24%                                                                                                       |
| 16.10%                                                                                                       |
| 0.064                                                                                                         |
| **3rd recurrence (%)**                                                                                        |
| 4/32                                                                                                          |
| 1.60%                                                                                                        |
| 4.51%                                                                                                        |
| 0.038                                                                                                         |
| **Age 1st at diagnosis**                                                                                     |
| 249/708                                                                                                       |
| 49.89 (17.62)                                                                                                 |
| 52.95 (17.10)                                                                                                 |
| 0.017                                                                                                         |
| **Age 2nd at diagnosis**                                                                                     |
| 88/303                                                                                                       |
| 55.78 (18.33)                                                                                                 |
| 58.42 (16.35)                                                                                                 |
| 0.280                                                                                                         |
| **Time between 1st and 2nd diagnosis**                                                                       |
| 88/303                                                                                                       |
| 4.97 (3.78)                                                                                                   |
| 4.37 (3.21)                                                                                                   |
| 0.268                                                                                                         |
| **Age at 3rd diagnosis**                                                                                     |
| 28/114                                                                                                       |
| 62.64 (17.83)                                                                                                 |
| 61.61 (15.47)                                                                                                 |
| 0.667                                                                                                         |
| **Time between 2nd and 3rd diagnosis**                                                                       |
| 28/114                                                                                                       |
| 3.57 (2.55)                                                                                                   |
| 3.79 (2.59)                                                                                                   |
| 0.589                                                                                                         |
| **Age at 4th diagnosis**                                                                                     |
| 4/32                                                                                                          |
| 59.25 (20.10)                                                                                                 |
| 63.97 (13.48)                                                                                                 |
| 0.752                                                                                                         |
| **Time between 3rd and 4th diagnosis**                                                                        |
| 4/32                                                                                                          |
| 3.75 (3.20)                                                                                                   |
| 3.50 (2.15)                                                                                                   |
| 0.942                                                                                                         |

Statistic used: Mann–Whitney U (Chi square and Fisher test were used for the percentage of subjects suffering a first, second or third recurrence).

https://doi.org/10.1371/journal.pone.0233454.t002
In the first episode, 13.69% of the patients were not prescribed pharmacological treatment, based on the criteria of their family physician; 45.45% were prescribed drugs for depression treatment in monotherapy, and 40.86% were prescribed polytherapy drug treatment. As for the patients who were not prescribed drug treatment in the first depression episode, their percentage rose to 13.69%, but it decreased over the following depression episodes. 80.9% of the patients who did not receive drug treatment in the first depression episode did not experience subsequent episodes; 16% experienced one subsequent episode and 3.1% experienced two subsequent episodes.

As for pharmacologic treatment, SSRIs and benzodiazepines, specifically paroxetine, escitalopram and lorazepam were the most frequently prescribed drugs for all depression episodes. This latter drug was prescribed mainly in combination with other medications. Paroxetine was prescribed to 27.48% of the patients in their first episode, to 26.11% in their second, to 25.92% in their third and 26.66% in their fourth episode. Escitalopram was prescribed to 14.048% of the patients in the first episode, to 18.61% in the second, to 26.67% in the third and to 26.66% in the fourth episode.

As for anxiolytics, the second therapeutic group prescribed as a complementary antidepressant treatment, lorazepam was prescribed to 26.27% of the patients in the first episode, to 21.66% in the second, to 21.48% in the third and to 23.33% in the fourth episode.

Monotherapy, and specifically, SSRIs were the most frequently prescribed treatment option for all depressive episodes. In all depression episodes, patients were mainly treated with a SSRI. Benzodiazepines and SNRIs were also prescribed slightly more often than the other therapeutic groups. No prescriptions of NRI, MRA or typical neuroleptics were prescribed in monotherapy.

As for combined pharmacologic treatment, in the first depression episode, a total of 50 different drug combinations were found: 29 combinations of drugs and 21 combinations of three medicines. There were 13 drug combinations prescribed to 86.96% of the patients via polytherapy. In the other depression episodes, the number of combinations was lower. The most frequent drug combinations were SSRIs and benzodiazepines. Tables 3–5 describe all types of treatments, both in monotherapy and polytherapy, for each depression episode.

### Discussion

The results of this retrospective cohort study reveal a percentage of the population in which recurrence of depressive episodes occurs frequently. In our study, 40% of all patients suffered at least one recurrence. The study by Solomon et al. [20] revealed higher numbers; 66% of the subjects having an initial depression episode experienced at least one recurrence during 10 years of follow up. Other studies [16,19,42] however, have suggested a lower prevalence, with recurrences taking place in approximately 33%, a figure which is more in line with our study.

As for the age in which the depression episodes were diagnosed, we have found high figures, given that the mean age at first diagnosis for men is 49.89 (SD: 17.62) and 52.95 in women.

**Table 3. Description (frequency and percentage) of treatment types (non-pharmacologic, monotherapy and polytherapy) for each depressive episode.**

| Treatment       | 1st episode Frequency (%) | 2nd episode Frequency (%) | 3rd episode Frequency (%) | 4th episode Frequency (%) |
|-----------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                 | N = 957                   | N = 391                   | N = 142                   | N = 36                    |
| Non-pharmacologic | 131 (13.69%)              | 31 (7.92%)                | 7 (4.93%)                 | 6 (16.66%)                |
| Monotherapy     | 435 (45.45%)              | 206 (52.69%)              | 83 (58.45%)               | 19 (52.78%)               |
| Polytherapy     | 391 (40.86%)              | 154 (39.39%)              | 52 (36.62%)               | 11 (30.56%)               |

https://doi.org/10.1371/journal.pone.0233454.t003
Table 4. Description (frequency and percentage) of pharmacologic treatment (ATC category) in monotherapy for each depression episode.

| Pharmacologic treatment | 1st episode Frequency (%) N = 435 | 2nd episode Frequency (%) N = 206 | 3rd episode Frequency (%) N = 83 | 4th episode Frequency (%) N = 19 |
|-------------------------|-----------------------------------|-----------------------------------|----------------------------------|-------------------------------|
| Benzodiazepine          | 47 (10.76%)                       | 18 (8.74%)                        | 6 (7.23%)                        | 2 (10.53%)                    |
| SSRI                    | 290 (66.66%)                      | 138 (66.99%)                      | 55 (66.27%)                      | 11 (57.89%)                   |
| TCA                     | 9 (2.06%)                         | 2 (0.97%)                         | 1 (1.20%)                        | 1 (5.26%)                     |
| SNRI                    | 40 (9.15%)                        | 21 (10.19%)                       | 15 (18.07%)                      | 2 (10.53%)                    |
| Heterocyclic            | 5 (1.14%)                         | 1 (0.49%)                         |                                  |                              |
| NDRIs                   | 3 (0.69%)                         | 1 (0.49%)                         |                                  |                              |
| SARI                    | 2 (0.46%)                         | 4 (1.94%)                         | 4 (4.82%)                        | 1 (5.26%)                     |
| NaSSA                   | 13 (2.97%)                        | 9 (4.37%)                         |                                  | 1 (5.26%)                     |
| SMS                     | 1 (0.23%)                         | 1 (0.49%)                         |                                  | 1 (5.26%)                     |
| Hypnotic                | 3 (0.69%)                         | 5 (2.43%)                         |                                  |                              |
| Anti-epileptic          | 1 (0.49%)                         |                                  |                                  | 1 (1.20%)                     |
| Atypical neuroleptics   | 3 (0.69%)                         | 1 (0.49%)                         |                                  |                              |
| Non-specific medicines   | 19 (4.35%)                        | 4 (1.94%)                         | 1 (1.20%)                        |                              |

SSRI, Selective Serotonin Reuptake Inhibitors; TCA, Tricyclic Antidepressants; SNRI, Serotonin–norepinephrine reuptake inhibitors; NDRI, Norepinephrine-dopamine reuptake inhibitors; SARI, Serotonin antagonist and reuptake inhibitors; NaSSA, Noradrenergic and specific serotonergic antidepressants; SMS, Serotonin activity modulator.

https://doi.org/10.1371/journal.pone.0233454.t004

Table 5. Description (frequency and percentage) of combined pharmacologic treatment (ATC classification) for each depressive episode.

| Pharmacological polytherapy | 1st episode Frequency (%) N = 391 | 2nd episode Frequency (%) N = 154 | 3rd episode Frequency (%) N = 52 | 4th episode Frequency (%) N = 11 |
|-----------------------------|-----------------------------------|-----------------------------------|----------------------------------|-------------------------------|
| Combination of 2 drugs      |                                   |                                   |                                  |                               |
| SSRI + benzodiazepine       | 218 (55.76%)                      | 79 (51.3%)                        | 28 (53.85%)                      | 8 (72.73%)                    |
| SSRI + non-specific medicine| 16 (4.10%)                        |                                  |                                  |                              |
| SSRI + NaSSA                | 6 (1.53%)                         | 4 (2.60%)                         | 4 (7.69%)                        |                              |
| SSRI + hypnotic             | 15 (3.83%)                        |                                  |                                  |                              |
| TCA + Benzodiazepine        | 8 (2.05%)                         |                                  |                                  |                              |
| SNRI + Benzodiazepine       | 32 (8.18%)                        | 14 (9.09%)                        | 4 (7.69%)                        |                              |
| SNRI + NaSSA                | 5 (1.95%)                         |                                  |                                  |                              |
| Heterocycle + Benzodiazepine| 4 (1.02%)                         |                                  |                                  |                              |
| Nonspecific medicine + Benzodiazepine | 8 (2.05%)            |                                  |                                  |                              |
| NaSSA + Benzodiazepine      | 5 (1.28%)                         |                                  |                                  |                              |
| SARI + Benzodiazepine       | 4 (2.60%)                         |                                  |                                  |                              |
| Benzodiazepine + Benzodiazepine | 7 (1.79%)                   | 4 (2.60%)                        |                                  |                              |
| Combination of 3 drugs      |                                   |                                   |                                  |                               |
| SSRI + 2 Benzodiazepine     | 12 (3.07%)                        |                                  |                                  |                              |
| SSRI + non-specific medicines + Benzodiazepine | 5 (1.28%) |                                  |                                  |                              |
| SNRI + NaSSA + Benzodiazepine| 4 (1.02%)                        |                                  |                                  |                              |
| SSRI + hypnotic + Benzodiazepine | 4 (2.60%)                       |                                  |                                  |                              |
| Other combinations with a frequency < = 3 subjects | 51 (13.04%) | 16 (30.77%) | 3 (27.27%) | |

SSRI, Selective Serotonin Reuptake Inhibitors; TCA, Tricyclic Antidepressants; SNRI, Serotonin–norepinephrine reuptake inhibitors; SARI, Serotonin antagonist and reuptake inhibitors; NaSSA, Noradrenergic and specific serotonergic antidepressants.

https://doi.org/10.1371/journal.pone.0233454.t005
In the study by Kessler and Bromet [6], the WHO World Mental Health (WMH) survey revealed that the median retrospectively-reported age of onset of depression episodes was the mid-20s, with the interquartile range indicating that across all countries, the peak risk period for the onset of MDD ranged from mid-late adolescence to the early 40s. In a study by Bockting et al [3], based on the World Mental Health Survey Initiative Version of the World Health Organization Composite International Diagnostic Interview (WMH-CIDI), the median age of onset (i.e., 50th percentile of the age-of-onset distribution) was the 30s for mood disorders. However, of the high income countries, Spain has one of the latest median ages of onset, at 30.0 years [6]. However, there may be other causes for this, including the failure of family physicians to diagnose younger patients, given the high population of immigrants in the healthcare system who are older [40], or since there may have been prior episodes that were not considered and that may have been omitted when transferring the clinical histories to electronic means due to patient mobility between health centers. As for the failure to diagnose, under-diagnosis and a difficulty of diagnosis occur in primary healthcare centers [43,44], since it is based on criteria and often not on very specific symptoms, which may be difficult to recognize by poorly trained professionals [45,46]. Although the most common stage of onset for mood disorders occurs during early adulthood (specifically, at the age of 30) [2], young adults do not tend to seek out health assistance given the related social stigma [47] or, in the case of young men from deprived backgrounds, they often fail to recognize a mental health problem and are less likely to suggest visiting a doctor than women [48].

In our research, the mean time between the first and second episode was 4.51 years (SD: 3.35), and this period was lower as the number of recurrences increased. This tendency has been seen previously in the bibliography, although the mean time of recurrence was lower, approximately 3 years for the time between the first and second episode and 1 to 1.5 years for subsequent episodes (Solomon et al., 2000). Additional research on the role of age as a sociodemographic factor is necessary, since in our study, a positive relationship was found between the number of recurrences and age, while in a review of naturalistic cohort studies [16], no association was found between this factor and the possibility of recurrence.

As for patients who are not prescribed drug treatment, this decision, made by the family physician, to not prescribe anything, may be related to the severity of the depressive episode, since disorder severity has been correlated with the probability of treatment [49]. In addition, clinical practice guidelines [32,50] have established recommendations for gradual treatment, based on scientific evidence; they recommend that the onset of intervention be the less intrusive of those that have been proven effective. In the computerized clinical history, the severity of the depression episode is not included. Therefore, it has been impossible to analyze whether these patients who did not receive pharmacological treatment were those having the mildest symptomology. A high percentage of these patients, (over 80%), however, did not experience recurrence.

According to current recommendations for antidepressants in patients suffering from unipolar depression [39], SSRIs and SNRI, more recently Duloxetine, Venlafaxine, and Desvenlafaxine, are the first line of treatment. These antidepressants were the most frequently consumed in our sample of patients, so we can assume that treatment for depression in primary care is consistent with clinical practice guideline recommendations.

Despite scientific evidence on the effectiveness and safety of these treatments, few studies have analyzed the relationship between antidepressant treatment and the recurrence of depression. In a meta-analysis conducted to establish the effectiveness of antidepressant treatment in preventing recurrence, 37 studies were analyzed, with 7,253 patients and comparing 24 different antidepressants with placebo. In 35 of these studies, antidepressant treatment was more effective than the placebo at preventing recurrence (RR = 2.03, CI 1.80–2.28, NNT = 3.8;
p < 0.0001), but no significant differences were observed regarding the different treatments analyzed [33]. Nevertheless, other research has found variations based on the administered treatment. In a double-blind study analyzing time to recurrence appearance, fluoxetine was found to produce a longer time to recurrence as compared to venlafaxine [51]. In another study in which the effectiveness of treatment was analyzed, in terms of 24 months without recurrences [52], it was found that bupropion and fluvoxamine were the least effective in preventing recurrence of depression. In this study, and in line with our results, duloxetine was more effective in this sense. The authors conclude that the balance between dopamine, serotonin and noradrenaline may play a major role in the prevention of recurrences. Thus, an increased dopaminergic activity may not be useful in this sense, as occurs with the use of bupropion alone. However, a dual action, such as treatment with SNRI, could provide protection from recurrences.

Based on this theory, in our cohort of patients, SNRI and NaSSA were the only treatments that were not related to recurrences. Both therapeutic groups present a different mechanism of action, but they share a simultaneous and specific action over serotonin and noradrenaline. Future studies should attempt to demonstrate this hypothesis.

With respect to the prescription of benzodiazepines, insomnia has been described as a potential modifier of antidepressant treatment response [53] and anxiety disorder has been found to have a direct negative effect on the overall course of the disease and the lack of response to pharmacological treatment [54–56]. A randomized double-blind study revealed that high levels of anxiety not only increase failure of acute treatments but also raise the risk of recurrences over the two years following episode remission, despite being used as an optimal antidepressant therapy [54]. This suggests that the preventive effect of SNRIs and NaSSAs can be neutralized depending on the nature of the depressive episode.

This study has numerous strengths, but it also faces certain limitations. On the one hand, it examines recurrences in a cohort of patients across a 16-year-period, not only from an epidemiologic point of view, but also based on pharmacologic treatment, providing a more comprehensive view of this phenomenon. Its limitations mainly relate to the information source, since some relevant data were not registered in the database, such as length of the treatment and duration of the depressive episode, or the severity of the same, and were not considered in the research. Severity of the depressive episode is not usually collected by primary care physician. The active ingredient dosage, although collected, has not been considered in the statistical analysis, since inclusion of this variable led to a loss of power in the results and caused confusion, especially with respect to combined drug treatment. The supposition is that the severity of those patients who did not receive drug treatment was milder, since this is the protocol recommended by clinical practice guidelines [32,50]. However, this relationship cannot be established since this variable is not included in the computerized clinical history. Further studies are needed to examine the relationship between seriousness and the duration of the pharmacological treatment, since both variables may shed light on the phenomenon of recurrence of depression [32].

Other aspects to be considered as study limitations include the diagnosis of depression made by the family physician, since as previously mentioned, there is an under-diagnosis in primary care [43,44]; and the existence of comorbidities. In this study, only serious psychiatric comorbidities have been considered as exclusion criteria. As for comorbidity, a study by Gili et al [12] that compared the comorbidity of affective disorders and medical diseases in primary care patients with either a first or recurrent depressive episode, revealed that all medical conditions were more prevalent in the recurrent patients group than in the first-episode group (aOR = 2.61, CI = 2.31–2.93), after adjusting for gender, age, education, socioeconomic status and body mass index. In this study, the suitability of drug treatment based on patient comorbidities has not been examined, given that the objective is to describe depressive episodes in a
primary care patient cohort and the administered pharmacologic treatment, from a naturalistic approach. Due to the universal nature of the healthcare system and the absence of other primary healthcare providers, it is known that subjects did not receive other pharmacological or psychological treatment from the healthcare system, but it is not known if they may have received some psychological therapy from outside of the national healthcare system. This may be considered a potential study limitation, since cognitive behavioral interventions, which may be carried out during the acute phase, appear to have a lasting protective effect on patients, preventing relapse and perhaps, recurrence upon treatment termination [3]. Finally, the sample has consisted mainly of female patients, as expected in Mediterranean countries in which women are almost three times more likely to suffer from MDD than men [57]. This fact, together with the aging population may further limit the generalization of our data. However, no clear influence of gender on antidepressant response has been reported in literature, at least for outpatients [58] and an aging population is a common demographic phenomenon in many developed countries.

Conclusion

Recurrence of depressive episodes is frequent in primary care patients, affecting more than 40% of the population, being more common in women. Monotherapy and specifically SSRIs were the most frequently prescribed treatment option for all depressive episodes. As for combined pharmacologic treatment, the most frequently prescribed drug combinations were SSRIs and benzodiazepines.

Acknowledgments

We wish to thank the Primary Care Prevention and Health Promotion Network (RedIAPP-Health Institute Carlos III, Spain); Research Group B21_R17 of the Department of Science, University and Knowledge Society of the Government of Aragon (Spain) and Feder Funds "Another way to make Europe".

Author Contributions

Conceptualization: Shysset Nuggerud-Galeas, Rosa Magallón Botaya, Bárbara Olivañ Blázquez.

Data curation: Shysset Nuggerud-Galeas.

Formal analysis: Rosa Magallón Botaya, Bárbara Olivañ Blázquez.

Investigation: Loreto Sáez-Benito Suescun, Nuria Berenguer Torrijo, Ana Sáez-Benito Suescun, Alejandra Aguilar-Latorre.

Methodology: Rosa Magallón Botaya, Bárbara Olivañ Blázquez.

Project administration: Rosa Magallón Botaya, Bárbara Olivañ Blázquez.

Resources: Rosa Magallón Botaya.

Supervision: Shysset Nuggerud-Galeas, Bárbara Olivañ Blázquez.

Validation: Bárbara Olivañ Blázquez.

Visualization: Alejandra Aguilar-Latorre, Bárbara Olivañ Blázquez.

Writing – original draft: Shysset Nuggerud-Galeas, Loreto Sáez-Benito Suescun, Nuria Berenguer Torrijo, Ana Sáez-Benito Suescun, Bárbara Olivañ Blázquez.
Writing – review & editing: Loreto Sáez-Benito Suescun, Nuria Berenguer Torrijo, Ana Sáez-Benito Suescun, Alejandra Aguilar-Latorre, Rosa Magallón Botaya, Bárbara Oliván Blázquez.

References

1. Roca M, GillI, Garcia-Garcia M, Salva J, Vives M, Garcia Campayo J, et al. Prevalence and comorbidity of common mental disorders in primary care. J Affect Disord [Internet]. 2009 Dec [cited 2019 Mar 25]; 119(1–3):52–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S016503270900127X PMID: 19361865

2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005; 62(6):593–602. https://doi.org/10.1001/archpsyc.62.6.593 PMID: 15939837

3. Bockting CL, Hollon SD, Jarrett RB, Kuyken W, Dobson K. A lifetime approach to major depressive disorder: The contributions of psychological interventions in preventing relapse and recurrence. Clin Psychol Rev [Internet]. 2015; 41:16–26. Available from: http://dx.doi.org/10.1016/j.cpr.2015.02.003 PMID: 25754289

4. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The Epidemiology of Major Depressive Disorder. JAMA [Internet]. 2003 Jun 18 [cited 2019 Sep 18]; 289(23):3095. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.289.23.3095 PMID: 12813115

5. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, et al. No health without mental health. Lancet [Internet]. 2007 Sep 8 [cited 2019 Sep 18]; 370(9590):859–77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17804063

6. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Heal. 2013; 34:119–38.

7. Bogren M, Brådvik L, Holmstrand C, Nöbbelin L, Mattisson C. Gender differences in subtypes of depression by first incidence and age of onset: a follow-up of the Lundby population. Eur Arch Psychiatry Clin Neurosci [Internet]. 2018 Mar 18 [cited 2019 Sep 18]; 268(2):179–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28315937

8. Mykletun A, Bjerkeset O, verland S, Prince M, Dewey M, Stewart R. Levels of anxiety and depression as predictors of mortality: the HUNT study. Br J Psychiatry [Internet]. 2009 Aug 2 [cited 2018 Jun 19]; 195(02):118–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19648541

9. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ [Internet]. 2006 Jun [cited 2019 Sep 18]; 9(2):87–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17007486

10. Sobocki P, Lekander I, Borgström F, Ström O, Runeson B. The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry [Internet]. 2007 Apr [cited 2018 Jun 19]; 22(3):146–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17194573

11. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet (London, England) [Internet]. 2007 Sep 8 [cited 2019 Sep 18]; 370(9590):851–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673607614159

12. GillI, Garcia-Toro M, Vives M, Armengol S, Garcia-Campayo J, Soriano JB, et al. Medical comorbidity in recurrent versus first-episode depressive patients. Acta Psychiatr Scand [Internet]. 2011 Mar [cited 2019 Sep 18]; 123(3):220–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21118188

13. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet (London, England) [Internet]. 2012 Mar 17 [cited 2018 Jun 19]; 379(9820):1045–55. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673611600028

14. Roca M, Armengol S, García-García M, Rodríguez-Bayón A, Ballesta I, Serrano MJ, et al. Clinical differences between first and recurrent episodes in depressive patients. Compr Psychiatry [Internet]. 2011 Jan [cited 2019 Sep 18]; 52(1):26–32. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0010440X10000453 PMID: 21220062

15. Frank E, Prien R, Jarrett R, Keller M, Kupfer D, Lavari P, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991; 48(9):851–5. https://doi.org/10.1001/archpsyc.1991.0181030075011 PMID: 1929776

16. Buckman JEJ, Underwood A, Clarke K, Saunders R, Hollon SD, Fearon P, et al. Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and
17. Monroe SM, Harkness KL. Recurrence in Major Depression: A Conceptual Analysis. Psychol Rev. 2011;

18. Monroe SM, Harkness KL. Is depression a chronic mental illness? Psychol Med [Internet]. 2012 May 14 [cited 2019 Sep 18]; 42(5):899–902. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21995936

19. Eaton WW, Shao H, Nestadt G, Lee BH, Bienvenu OJ, Zandi P, et al. Population-Based Study of First Onset and Chronicity in Major Depressive Disorder. Arch Gen Psychiatry [Internet]. 2008 May 1 [cited 2019 Sep 16]; 65(5):513. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18458203

20. Solomon DA, Keller MB, Leon AC, Mueller PW, Shea MT, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry [Internet]. 2000 Feb 1 [cited 2019 Sep 16]; 157(2). Available from: http://ajp.psychiatryonline.org/article.aspx?articleID=173950

21. Solomon DA. Multiple Recurrences of Major Depressive Disorder. Am J Psychiatry. 2000 Feb; 157(2):229–33. https://doi.org/10.1176/appi.ajp.157.2.229 PMID: 10671391

22. Hoertel N, Blanco C, Oquendo MA, Wall MM, Olfson M, Falissard B, et al. A comprehensive model of predictors of persistence and recurrence in adults with major depression: Results from a national 3-year prospective study. J Psychiatr Res [Internet]. 2017 Dec [cited 2018 Jun 18]; 95:19–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28759845

23. Steinert C, Hofmann M, Kruse J, Leichsenring F. The prospective long-term course of adult depression in general practice and the community. A systematic literature review. J Affect Disord [Internet]. 2014 Jan [cited 2019 Sep 18]; 152–154:65–75. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0165032713007465 PMID: 24210624

24. Spijker J, de Graaf R, ten Have M, Nolen WA, Speckens A. Predictors of suicidality in depressive spectrum disorders in the general population: results of the Netherlands Mental Health Survey and Incidence Study. Soc Psychiatry Psychiatr Epidemiol [Internet]. 2010 May 19 [cited 2019 Sep 18]; 45(5):513–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19618093

25. Grieve SM, Korgaonkar MS, Koslow SH, Williams LM. Widespread reductions in gray matter volume in depression. NeuroImage Clin [Internet]. 2013 [cited 2019 Sep 18]; 3:332–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24273717

26. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A Meta-Analysis of Cytokines in Major Depression. Biol Psychiatry [Internet]. 2010 Mar 1 [cited 2019 Sep 18]; 67(5):446–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20015486

27. Patten SB, Wang JL, Williams JV, Lavorato DH, Khaled SM, Bulloch AG. Predictors of the Longitudinal Course of Major Depression in a Canadian Population Sample. Can J Psychiatry [Internet]. 2010 Oct [cited 2019 Sep 18]; 55(10):669–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20964946

28. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. J Affect Disord [Internet]. 2009 Oct [cited 2019 Sep 18]; 117:S26–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19674794

29. Wang JL, Patten SB, Currie S, Sareen J, Schmitz N. Predictors of 1-year outcomes of major depressive disorder among individuals with a lifetime diagnosis: a population-based study. Psychol Med [Internet]. 2012 Feb 11 [cited 2019 Sep 18]; 42(2):327–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21740627

30. Hirschfeld RM. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl [Internet]. 2001 Sep [cited 2019 Sep 18]; 42:S4–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11532820

31. Gartlehner G, Hansen R, Morgan L, Thaler K, Lux L, Van Noord M, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;6(155(11)):772–85. PMID: 22147715

32. Álvarez M, Atienza Merino G, José GÁM, González García A, Guitián Rodríguez D, De las Heras Liñero E, et al. Guía de Práctica Clínica sobre el manejo de la depresión en el adulto. Minist Sanidad, Serv Soc e Igualdad Agencia Evaluación Tecnol Sanit Galicia. 2014; 6(2):38–41.

33. Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials. Int J Neuropsychopharmacol [Internet]. 2016 Feb 7 [cited 2019 Sep 18]; 19(2):pyv076. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26152228

34. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, et al. Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder. Ann Intern Med [Internet]. 2011 Dec 6 [cited 2019 Sep 18]; 155(11):772. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22147715
35. Hansen R, Gaynes B, Thieda P, Gartlehner G, Deveaughe-Geiss A, Krebs E, et al. Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants. Psychiatr Serv [Internet]. 2008 Oct 1 [cited 2019 Sep 18]; 59(10):1121–30. Available from: http://ps.psychiatryonline.org/article.aspx?articleID=99788 PMID: 18832497

36. Serna C, Cruz I, Galván L, Real J, Gascó E, Soler-González J. Evolution of the prevalence and incidence of consumption of antidepressants in a Spanish region (2002–2007). Ment Health Fam Med [Internet]. 2010 Mar [cited 2019 Sep 18]; 7(1):9–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20747718

37. Abbing-Karahagopian V, Huerta C, Souverein PC, de Abajo F, Leufkens HGM, Slattery J, et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. EUR J Clin Pharmacol [Internet]. 2014 Jul 3 [cited 2019 Sep 18]; 70(7):849–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24793010

38. Gomez-Lumbraeras A, Ferrer P, Bailer E, Sabaté M, Vidal X, Andretta M, et al. Study of antidepressant use in 5 European settings. Could economic, sociodemographic and cultural determinants be related to their use? J Affect Disord [Internet]. 2014 Jul 3 [cited 2019 Sep 18]; 165(7):1000–6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0165032714009729

39. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry [Internet]. 2013 Jul 3 [cited 2019 Sep 18]; 14(5):334–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23879318

40. Padrón Municipal. Cifras de Zaragoza 2017. Zaragoza; 2017.

41. General Council of Official Pharmaceutical Colleges. Bot Plus. Health Knowledge Database. Madrid; 2018.

42. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry [Internet]. 1999 Jul [cited 2019 Sep 18]; 156(7):1000–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10401442

43. Bhattacharjee S, Goldstone L, Valdei N, Lee JK, Burke WJ. Depression Screening Patterns, Predictors, and Trends Among Adults Without a Depression Diagnosis in Ambulatory Settings in the United States. Psychiatr Serv [Internet]. 2018 Oct 1 [cited 2020 Apr 12]; 69(10):1098–100. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29983110

44. Montes-S-Curto P, Ferré-Grau C, Lleixà-Fortuño M, Albacar-Ribóo N, Lejeune M. Dignosed, Identified, Current and Complete Depression Among Patients Attending Primary Care in Southern Catalonia: Different Aspects of the Same Concept. Arch Psychiatr Nurs [Internet]. 2014 Feb [cited 2020 Apr 12]; 28(1):50–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24506987

45. Cameron C, Habert J, Anand L, Furtado M. Optimizing the management of depression: primary care experience [Internet]. Vol. 220. Psychiatry Research. Elsevier Ireland Ltd; 2014 [cited 2020 Apr 12], p. S45–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25539874

46. Gabilondo A, Rojas-Farreras S, Rodríguez A, Fernández A, Pinto-Meza A, Vilagut G, et al. Use of primary and specialized mental health care for a major depressive episode in Spain by ESEMeD respondents. Psychiatr Serv [Internet]. 2011 Feb [cited 2020 Apr 12]; 62(2):152–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21285093

47. Martínez-Hernández A, DiGiacomo SM, Carceller-Maicas N, Correa-Urquiza M, Martorell-Poveda MA. Non-professional-help-seeking among young people with depression: a qualitative study. BMC Psychiatry [Internet]. 2014 Apr 28 [cited 2020 Apr 14]; 14(1):124. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24774644

48. Klineberg E, Biddle L, Donovan J, Gunnell D. Symptom recognition and help seeking for depression in young adults: A vignette study. Soc Psychiatry Psychiatr Epidemiol [Internet]. 2011 Jun [cited 2020 Apr 14]; 46(6):495–505. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20358174

49. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. Vol. 291. Journal of the American Medical Association. American Medical Association; 2004, p. 2581–90.

50. National Clinical Practice Guideline. Depression: Treatment and management of depression in adults. NICE Guideline. London, United Kingdom; 2009.

51. Thase ME, Gelenberg A, Kornstein SG, Kocsis JH, Trivedi MH, Ninan P, et al. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: Results from the PREVENT study. J Psychiatr Res [Internet]. 2011 Mar [cited 2019 Sep 18]; 45(3):412–20. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022395610002219 PMID: 20801464
52. Buoli M, Cumerlato Melter C, Caldirola A, Altamura AC. Are antidepressants equally effective in the long-term treatment of major depressive disorder? Hum Psychopharmacol Clin Exp [Internet]. 2015 Jan [cited 2019 Sep 18]; 30(1):21–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25393889

53. Noma H, Furukawa TA, Maruo K, Imai H, Shinohara K, Tanaka S, et al. Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. J Affect Disord [Internet]. 2019 May 1 [cited 2019 Sep 18]; 250:419–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30878654

54. Andreescu C, Lenze EJ, Dew MA, Begley AE, Mulsant BH, Dombrovski AY, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry [Internet]. 2007 Apr 2 [cited 2019 Sep 18]; 190(4):344–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17401042

55. Perlis RH. A Clinical Risk Stratification Tool for Predicting Treatment Resistance in Major Depressive Disorder. Biol Psychiatry [Internet]. 2013 Jul [cited 2019 Sep 18]; 74(1):7–14. Available from: https://linkinghub.elsevier.com/retrieve/pii/S000632231201092X PMID: 23380715

56. Mulsant BH, Reynolds CF, Shear MK, Sweet RA, Miller M. Comorbid anxiety disorders in late-life depression. Anxiety [Internet]. 1996 [cited 2019 Sep 18]; 2(5):242–7. Available from: http://doi.wiley.com/10.1002%28SICI%291522-7154%281996%292%3A5%3C242%3A%3AAID-ANXI6%3E3.0.CO %3B2-O PMID: 9160629

57. Gabilondo A, Rojas-Farreras S, Vilagut G, Haro JM, Fernández A, Pinto-Meza A, et al. Epidemiology of major depressive episode in a southern European country: results from the ESEMeD-Spain project. J Affect Disord [Internet]. 2010 Jan [cited 2018 Jun 19]; 120(1–3):76–85. Available from: http://linkinghub.elsevier.com/retrieve/pii/S016503270900161X PMID: 19428121

58. Scheibe S, Preuschhof C, Cristi C, Bagby RM. Are there gender differences in major depression and its response to antidepressants? J Affect Disord [Internet]. 2003 Aug [cited 2019 Sep 17]; 75(3):223–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12880935